A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2018
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics
- Acronyms SCIG03
- Sponsors Bio Products Laboratory
- 04 Aug 2017 Status changed from active, no longer recruiting to completed.
- 03 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 May 2017.
- 03 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 May 2017.